2023 8 8

1

4

6

7

8

1. 9

2. 10

2024

		+6.3	*48.3*									
		+7.1	—									
		+4.5	—									
		0.4	—									
		+8.1	*60.9*									
		27.6	*58.0*									

2023

									—	3,068	5.1	—
									—	2,313	+0.5	—
						—	147	10.2	—	189	13.6	—
		7.9	—	157	5.5	—	253	+0.5	—	341	+6.2	—
						—	580	1.6	—	777	0.8	—
		3.1	*44.0*	431	14.2	+5.3	647	18.1	*83.5*	754	18.8	2.7
		3.5	*44.4*	439	15.2	+5.8	663	19.1	*87.3*	741	21.1	2.4
		+28.2	*51.7*	333	8.9	+7.7	472	15.8	*76.2*	694	20.7	+11.9

2024

		—	5,632	+9.0	
			1,700	2.4	
1,554	5.4				
1,122	1.5	1,190	+2.4	2,313	+0.5
100	2.2	88	23.6	189	13.6
157	5.5	183	+18.8	341	+6.2
386	1.7	391	0.0	777	0.8
431	14.2	322	24.3	754	18.8
439	15.2	302	28.3	741	21.1
333	8.9	360	29.1	694	20.7

2023	180	145	38	2	431	293	146	7	647	451	210	14	754	558	217	21
	+101	+100	+1	—												
	8	—	8	—												
	92	90	2	—												
	+0	10	+10	—												
	+13	+7	+7	0												
	+14	+6	+7	0												
2024	194	152	46	3												

90

2

8

2

+3

+6

2023	431	293	146	7	322	265	70	13	754	558	217	21
	+238	+264	26	—	+329	+232	+97	—	+567	+496	+71	—
	16	—	16	—	18	—	18	—	34	—	34	—
	196	188	8	—	124	119	5	—	320	307	13	—
	98	86	12	—	53	81	+28	—	151	167	+16	—
	39	24	11	4	+2	+3	+3	4	37	21	8	8
	111	34	73	4	+137		+106	4	+25	+1	+32	8

2024					
	11,717	+3.1			
	5,028	+6.8			
	6,689	+0.5			
	4,096	+6.4			
	2,913	+9.4			
	1,182	0.3			
	7,620	+1.4			
	6,634	0.2			
)	1,014	+57.7			
	8,226	0.0			
(	3,199	1.9			

6,689

+3.3

		KD2-305		VIII	IX			
		ME3208			(cGVHD)	ROCK2		
	*	DMB-3115		/	/	/	*	ST
Phase I							*	Intas Pharmaceuticals Ltd.
Phase III		HBI-8000						HUYABIO International
Phase III		OP0595	β -					
Phase II		ME3183		PDE4				
Phase Ib / II		HBI-8000		B				HUYABIO International

P ationa

2023 8 8